title: Enhanced expression of human β-defensin 2 in peripheral lungs of patients with chronic obstructive pulmonary disease.
abstract: Human β-defensin 2 (hBD-2) has antimicrobial activity and may play a role in airway mucosal defense, but studies have not yet examined its expression in lung tissue of patients with chronic obstructive pulmonary disease (COPD). Here we investigated hBD-2 levels in lung tissues of COPD patients and analyzed their correlations with IL-8, IL-1β, cigarette smoking and lung function in order to see whether the protein may be involved in pathogenesis of the disease. Peripheral lung tissue specimens were obtained from 51 patients who underwent lung resection for peripheral lung cancer: healthy non-smokers (n=8), healthy current smokers (n=7), non-smokers with COPD (n=11), and current smokers with COPD (n=25). RT-PCR and immunohistochemical staining were used to detect expression levels of hBD-2, IL-8 and IL-1β. Expression of hBD-2 mRNA was significantly higher in COPD patients than in healthy controls, and significantly higher in current smokers than in non-smokers (p<0.05). Among healthy controls, hBD-2 mRNA levels were similar between current smokers and non-smokers. Immunohistochemistry showed hBD-2 protein to be expressed mainly in epithelia of distal bronchioles and its expression pattern among our patient groups mirrored that of the mRNA. IL-8 mRNA levels were significantly higher in COPD patients than in healthy controls (p<0.05), while IL-1β mRNA levels did not differ significantly among the groups. Levels of hBD-2 mRNA positively correlated with levels of IL-8 mRNA (r=0.545, p=0.002), and negatively correlated with FEV1/FVC ratios and with predicted FEV1% values (r=-0.406, p=0.011). Our results indicate that hBD-2 expression is elevated in distal airways of COPD patients and that it may be involved in pathogenesis of the disease. Our data implicate cigarette smoking as a factor that may elevate hBD-2 levels in lung tissues of COPD patients.
authors.affiliation: Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, and Department of Respiratory Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China. liaozenglin@163.com
authors.forename: Zenglin
authors.initials: Z
authors.lastname: Liao
authors.forename: Jiajia
authors.initials: J
authors.lastname: Dong
authors.forename: Xiaorong
authors.initials: X
authors.lastname: Hu
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.forename: Chun
authors.initials: C
authors.lastname: Wan
authors.forename: Xiao'ou
authors.initials: X
authors.lastname: Li
authors.forename: Lin
authors.initials: L
authors.lastname: Li
authors.forename: Lingli
authors.initials: L
authors.lastname: Guo
authors.forename: Dan
authors.initials: D
authors.lastname: Xu
authors.forename: Fuqiang
authors.initials: F
authors.lastname: Wen
mesh_terms: D006801:Humans; D007150:Immunohistochemistry; D053583:Interleukin-1beta / Q000235:genetics; D016209:Interleukin-8 / Q000235:genetics; D029424:Pulmonary Disease, Chronic Obstructive / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D023083:beta-Defensins / Q000032:analysis / Q000235:genetics*
chemical_list: C106641:DEFB4A protein, human; D053583:Interleukin-1beta; D016209:Interleukin-8; D012333:RNA, Messenger; D023083:beta-Defensins